Medical Strategy

Your asset sits at the heart of our medical strategy. To tailor the right approach, we use a multifaceted strategy considering all our skills, connections, and wide network to meet the needs of your product. In doing so, we tailor appropriate medical strategies that connect clinical evidence and core value messages in the most impactful way.

We collaborate closely with our partners throughout the commercialisation process, focusing on gaining a thorough understanding of the product requirements and the value of the asset to you before we start to tailor the most appropriate strategy. From content, key congresses and stakeholder engagement to channel tactics using state-of-the-art market intelligence, we then dovetail our strategy to meet the needs of your product.

Finding the essential market fit

Our expertise and experience in working with rare disease products and orphan drugs in Europe makes us well placed to take your asset and find the appropriate solution that will give it the best chance of sustainable success. We use our skills, analytics, and insights teams along with our on the ground in market teams and advisory boards to understand where it fits in the market and explore the full potential of the drug. This knowledge equips us with the ability to see the blind spots in the market and know what to communicate to the key stakeholders, as well as when to communicate with them. We are then able to create content that can be shared with them, either in person or via congresses and conferences, and understand how to position the drug and its key benefits to best effect.

Collaborating with teams of experts

Our deep experience working with rare disease products in the European market means that we have a network of trusted medical advisors to call on when it comes to drug launch. This provides us with deep insights into the rare disease in the market in question, allowing us to best understand how to share data and details of the drug, how to get it prescribed, and how best to educate patients and prescribers about the drug and its capabilities. We play a key role in shaping the medical narrative around the drug and in working with healthcare professionals to drive the best result.

Networked teams working together

One of the key benefits of working with Abacus Medicine Pharma Services is that the entire commercialisation process is offered as an end-to-end solution, and that our departments work together in cross-functional teams, streamlining the process overall. Our regulatory teams collaborate closely with our medical strategists, confirming that the complex web of regulatory requirements is adhered to, while also collaborating with our market access teams to ensure we are best placed in opportunity markets. The complete solution saves time and allows for a flow of information across departments, thereby optimising the market potential.

Working across the drug’s lifecycle

While much of the medical strategy we employ is about preparing the market for the drug’s launch, and establishing the conditions for it, the work does not end when the drug is available in the market. Our analytics and insights teams provide regular updates to the strategy team, allowing us to explore future expansion, strategic changes and address any emerging safety concerns. By doing this, we can ensure the drug has the longest possible successful lifespan in the market, and it continues to meet the needs of patients and healthcare systems as far into the future as possible.